2 min listen
Inside the World's First-Ever Allogeneic Approval with Atara Biotherapeutics' Pascal Touchon
Inside the World's First-Ever Allogeneic Approval with Atara Biotherapeutics' Pascal Touchon
ratings:
Length:
41 minutes
Released:
Mar 30, 2023
Format:
Podcast episode
Description
In December 2022, Atara Biotherapeutics’ Ebvallo received European Commission approval as the first-ever therapy for adults and children with EBV+ PTLD. The ground-breaking approval represents the first approval of an allogeneic T-cell immunotherapy ever, globally. Atara Bio's CEO, Pascal Touchon, talks to Cell & Gene: The Podcast's Erin Harris about the biopharma's path to regulatory approval, commercialization plans for Ebvallo, an in-depth look at EBV+ PTLD, the connection between EBV and serious diseases like multiple sclerosis (MS), and much more.
Released:
Mar 30, 2023
Format:
Podcast episode
Titles in the series (76)
Introducing Cell & Gene: The Podcast by Cell & Gene: The Podcast